SCHEMBL4014167

SCHEMBL4014167

CC(C)CC(CNC(=O)CCC(C)CN)CC(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 2/20 0.54
CACNB3 P54284 1/20 0.54
CACNA1C Q13936 1/20 0.54
PGR P06401 1/20 0.54
ADRA1A P35348 1/20 0.54
HTR2B P41595 1/20 0.54
CACNA2D2 Q9NY47 1/20 0.54
ALDH1A1 P00352 1/20 0.33
CTSC P53634 1/20 0.33
HPGD P15428 1/20 0.32
FOLH1 Q04609 4/20 0.31
ANPEP P15144 1/20 0.31
DNPEP Q9ULA0 1/20 0.31
EGLN2 Q96KS0 1/20 0.31
EGLN1 Q9GZT9 1/20 0.31
SLC1A2 P43004 1/20 0.31
SLC1A1 P43005 1/20 0.31
PLA2G10 O15496 1/20 0.31
MMP2 P08253 1/20 0.30
MMP9 P14780 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4006243 0.89 CACNA2D1 (0.41) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL4005365 0.88 CACNA2D1 (0.40) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL4007045 0.85 CACNA2D1 (0.38) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL4009312 0.82 CACNA2D1 (0.59) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL4007894 0.82 CACNA2D1 (0.59) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL4010378 0.81 CACNA2D1 (0.51) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL4015383 0.77 ALDH1A1 (0.33) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL17292615 0.77 PLA2G10 (0.50) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL17292613 0.77 PLA2G10 (0.50) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL17292598 0.75 PLA2G10 (0.52) CACNA2D1CACNB3CACNA1CPGRADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491835-B2 Prodrugs of amino acids with affinity for the α2δ-protein PFIZER INC (US) 2009-02-17 US claimed
US-20050070483-A1 Prodrugs of amino acids with affinity for the alpha2delta-protein VIATRIS SPECIALTY LLC. 2005-03-31 US claimed
US-7491835-B2 Prodrugs of amino acids with affinity for the α2δ-protein PFIZER INC (US) 2009-02-17 US disclosed
EP-1670750-A1 PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN Warner-Lambert Company LLC (US) 2006-06-21 EP disclosed
WO-2005030703-A1 PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN WARNER-LAMBERT COMPANY LLC (US) 2005-04-07 WO disclosed
US-20050070483-A1 Prodrugs of amino acids with affinity for the alpha2delta-protein VIATRIS SPECIALTY LLC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070483-A1 Prodrugs of amino acids with affinity for the alpha2delta-protein SCN2A, OPRD1, SCN1A CACNA2D1 40/4885CACNB3 77/4885CACNA1C 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.